Abstract:Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEGF isoforms (VEGF120, 164 or 188), grown in vitro and in vivo, and compared results with those from normal mouse and human tissues. Importantly, genetic construction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the conventional exon 8, precludes VEGFxxxb splicing from occurring. Thus, these two fibrosarcoma cell lines provided endogenous negative controls. Using RT-PCR we show that primers designed to simultaneously amplify VEGFxxx and VEGFxxxb isoforms amplified only VEGFxxx variants in both species. Moreover, only VEGFxxx species were generated when mouse podocytes were treated with TGFβ-1, a reported activator of VEGFxxxb splice selection in human podocytes. A VEGF164/120 heteroduplex species was identified as a PCR artefact, specifically in mouse. VEGFxxxb isoform-specific PCR did amplify putative VEGFxxxb species in mouse and human tissues, but unexpectedly also in VEGF188 and VEGF164 fibrosarcoma cells and tumours, where splicing to produce true VEGFxxxb isoforms cannot occur. Moreover, these products were only consistently generated using reverse primers spanning more than 5 bases across the 8b/7 or 8b/5 splice junctions. Primer annealing to VEGFxxx transcripts and amplification of exon 8b primer 'tails' explained the artefactual generation of VEGFxxxb products, since the same products were generated when the PCR reactions were performed with cDNA from VEGF164/VEGF188 'knock-in' vectors used in the generation of single VEGF isoform-expressing transgenic mice from which the fibrosarcoma lines were developed. Collectively, our results highlight important pitfalls in data interpretation associated with detecting VEGFxxxb isoforms using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in mouse or human tissues.

The Evolution of Alternative Splicing Exons in Vascular Endothelial Growth Factor A

Advance in Inhibitory Splice Variant VEGF165b

Alternative Splicing in Angiogenesis

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale

Synthetic Antiangiogenic Vascular Endothelial Growth Factor-A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease

Evolution of Alternative Splicing in Newly Evolved Genes of Drosophila.

Evolution of Peroxisome Proliferator-Activated Receptor Gamma Alternative Splicing

VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

Alternative splicing of VEGFA is regulated by RBM10 in endometrial cancer

Origin And Evolution Of New Exons In Rodents

Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors

Identification and Characterization of the Alternative Splicing Variants of Rat RVLG

Alternative Splicing of Cav1.2 Channel Exons in Smooth Muscle Cells of Resistance-Size Arteries Generates Currents with Unique Electrophysiological Properties.

The Expanding Role of Alternative Splicing in Vascular Smooth Muscle Cell Plasticity

Therapeutic potential of alternative splicing in cardiovascular diseases

The alternative splicing landscape of infarcted mouse heart identifies isoform level therapeutic targets

Alternative splicing and evolution: diversification, exon definition and function

Tissue Usage Preference and Intrinsically Disordered Region Remodeling of Alternative Splicing Derived Proteoforms in the Heart

Alternative splicing: Human disease and quantitative analysis from high-throughput sequencing

Nanopore long-read RNA sequencing reveals functional alternative splicing variants in human vascular smooth muscle cells